NASDAQ:ALBT Avalon GloboCare 11/12/2024 Earnings Report $0.35 +0.01 (+3.53%) As of 02:07 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Avalon GloboCare EPS ResultsActual EPS-$1.82Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAvalon GloboCare Revenue ResultsActual Revenue$0.35 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAvalon GloboCare Announcement DetailsQuarterDate11/12/2024TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Avalon GloboCare Earnings HeadlinesExclusive: Avalon GloboCare gets $125K conditional grant for teaming with AWS for 'agentic' AI video platformApril 21, 2026 | msn.comAvalon Quantum AI teams up with Caylent and Amazon Web Services on Agentic AI Platform DevelopmentApril 21, 2026 | globenewswire.comThe chokepoint supplier behind SpaceX's $1.75 trillion empireWhen Musk laughed and said 'you need transformers to run transformers,' it wasn't a joke - it was a confession. The world's largest supercomputer requires power equipment that takes 120 weeks to build, and Musk built Colossus in just 122 days. One small American company is positioned to close that gap faster than anyone else, yet Wall Street still prices it like an afterthought. Dylan Jovine has the full story and the ticker.May 22 at 1:00 AM | Behind the Markets (Ad)Avalon GloboCare (ALBT) surges over 36% after hours: Here's what is happeningApril 9, 2026 | msn.comAvalon GloboCare (ALBT) Surges Over 36% After Hours: Here's What Is HappeningApril 9, 2026 | benzinga.comAvalon GloboCare Corp.April 1, 2026 | edition.cnn.comSee More Avalon GloboCare Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Avalon GloboCare? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avalon GloboCare and other key companies, straight to your email. Email Address About Avalon GloboCareAvalon GloboCare (NASDAQ:ALBT) is a clinical-stage biopharmaceutical company specializing in the research, development and commercialization of next-generation cell-based therapies and exosome-based diagnostics. The company’s pipeline focuses on allogeneic chimeric antigen receptor T-cell (CAR-T) and CAR-natural killer (CAR-NK) programs targeting hematological malignancies and solid tumors, alongside proprietary exosome platforms for noninvasive cancer detection. Through its R&D facilities in both the United States and China, Avalon GloboCare integrates cell engineering, genetic modification and biomarker discovery to advance therapeutic and diagnostic candidates from preclinical research into human studies. Its technology platforms include exoSTAMP, designed for highly sensitive isolation and analysis of circulating exosomes, and exoSC, aimed at scalable manufacturing of exosome-based products. The company maintains strategic collaborations with academic and clinical partners to accelerate development timelines and broaden the potential application of its technologies. These partnerships support Avalon’s efforts to optimize manufacturing processes, refine product specifications and initiate clinical trials in oncology and, potentially, viral diseases where cell therapy approaches can address unmet medical needs. Founded in 2016 and publicly listed on NASDAQ under the ticker ALBT, Avalon GloboCare is led by Dr. Leem Chao, its Chairman and Chief Executive Officer. Under his leadership, the company has expanded its footprint across key biopharma hubs and continues to advance a diversified portfolio of innovative therapies and diagnostics designed to improve patient outcomes worldwide.View Avalon GloboCare ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Overextended, e.l.f. Beauty Is Primed to Rebound in Back HalfDeere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookNVIDIA Price Pullback? Don’t Count on It, Business Is AcceleratingMeta Platforms 10% Layoff Raises a Bigger Question About AI SpendingBiogen Stock Slides After Trial Miss, But Analysts Stay BullishTarget Shows Strengths, But Analysts Want to See MoreLowe's Finds Support at $215 After Q1 Earnings Sell-Off Upcoming Earnings AutoZone (5/26/2026)Marvell Technology (5/27/2026)PDD (5/27/2026)Synopsys (5/27/2026)Bank Of Montreal (5/27/2026)Bank of Nova Scotia (5/27/2026)Salesforce (5/27/2026)Snowflake (5/27/2026)Autodesk (5/28/2026)Costco Wholesale (5/28/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
